ENDPOINTS

Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

In the biggest biopharma deal since January, Sanofi is bolstering its rare immunology offering by acquiring Blueprint Medicines for $9.1 billion. The French drugmaker has agreed to pay $129 per share in cash for Blueprint ...

Jun 2, 2025 - 12:24
 0
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B
In the biggest biopharma deal since January, Sanofi is bolstering its rare immunology offering by acquiring Blueprint Medicines for $9.1 billion. The French drugmaker has agreed to pay $129 per share in cash for Blueprint ...
Read More

Tags:

Previous Article

The global temperature may be even higher than we thought

Next Article

Securing Amazonia cities for a resilient and sustainable planet

Related Posts

Vera posts positive Phase 3 rare kidney disease data, but crowded market looms

Vera posts positive Phase 3 rare kidney disease data, b...

Jun 2, 2025  0

Trump unofficially taps CMS chief Oz to spearhead 'most favored nation' talks

Trump unofficially taps CMS chief Oz to spearhead 'most...

May 23, 2025  0

Genentech expands partnership with molecular glue biotech Orionis

Genentech expands partnership with molecular glue biote...

May 21, 2025  0